Novozymes, the Copenhagen-based industrial enzymes company, will receive a European Investment Bank (EIB) financing facility for its research, development and innovation activities under an agreement signed today.
The financing facility is aimed at projects in enzymes, novel proteins and micro-organisms at Novozymes, the world’s largest producer of industrial enzymes. With activities that are solidly in line with the European Union’s objectives of strengthening the knowledge economy, the company improves industrial processes with technology that replace conventional chemicals, improve resource efficiency and reduce environmental impact.
Background information:
The mission of the EIB, the European Union’s bank, is to contribute to the integration, balanced development and economic and social cohesion of the EU Member States by financing sound investments. The European Investment Bank is the long-term lending institution of the European Union, whose shareholders are the 27 member states. This loan is one of many supporting the EU Strategy for the Baltic Sea Region and its four priorities: sustainable environment; regional prosperity; increased accessibility and attractiveness; safety and security.
Novozymes is the world leader in bioinnovation. Together with customers across a broad array of industries the company creates tomorrow’s industrial biosolutions, improving its customers' business, and the use of our planet's resources. With over 700 products used in 130 countries, Novozymes’ bioinnovations improve industrial performance and safeguard the world’s resources by offering superior and sustainable solutions for tomorrow’s ever-changing marketplace.